The FINGER trial found a slower cognitive decline in individuals assigned to the multi-domain intervention [50], while in the other two trials (PREDIVA and MAPT trials) protective effects were observed under specific circumstances (e.g., those with more vascular factors, higher future dementia risk scores, brain amyloid positivity or carriers of the e4 allele of Apolipoprotein E) [48,49]. Here, APOE is linked to dementia.